These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 20934397)

  • 1. Recent advances in the understanding of the role of the endocannabinoid system in liver diseases.
    Huang L; Quinn MA; Frampton GA; Golden LE; DeMorrow S
    Dig Liver Dis; 2011 Mar; 43(3):188-93. PubMed ID: 20934397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases.
    Pacher P; Gao B
    Am J Physiol Gastrointest Liver Physiol; 2008 Apr; 294(4):G850-4. PubMed ID: 18239059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocannabinoids in liver disease.
    Tam J; Liu J; Mukhopadhyay B; Cinar R; Godlewski G; Kunos G
    Hepatology; 2011 Jan; 53(1):346-55. PubMed ID: 21254182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The endocannabinoid system in cholestasis.
    Floreani A; Pizzuti D; Bergasa NV; Petrosino S
    Dig Liver Dis; 2011 Dec; 43(12):1026-7. PubMed ID: 21816694
    [No Abstract]   [Full Text] [Related]  

  • 5. Review article: the endocannabinoid system in liver disease, a potential therapeutic target.
    Basu PP; Aloysius MM; Shah NJ; Brown RS
    Aliment Pharmacol Ther; 2014 Apr; 39(8):790-801. PubMed ID: 24612021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver.
    Mallat A; Lotersztajn S
    Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G9-G12. PubMed ID: 17975129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocannabinoids signaling: Molecular mechanisms of liver regulation and diseases.
    Wang M; Meng N; Chang Y; Tang W
    Front Biosci (Landmark Ed); 2016 Jun; 21(7):1488-501. PubMed ID: 27100518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocannabinoids in liver disease and hepatic encephalopathy.
    Magen I; Avraham Y; Berry E; Mechoulam R
    Curr Pharm Des; 2008; 14(23):2362-9. PubMed ID: 18781986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocannabinoids as novel mediators of liver diseases.
    Mallat A; Lotersztajn S
    J Endocrinol Invest; 2006; 29(3 Suppl):58-65. PubMed ID: 16751709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling.
    Frampton G; Coufal M; Li H; Ramirez J; DeMorrow S
    Exp Cell Res; 2010 May; 316(9):1465-78. PubMed ID: 20347808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholangiocarcinomas arising in cirrhosis and combined hepatocellular-cholangiocellular carcinomas share apomucin profiles.
    Sasaki M; Nakanuma Y; Ho SB; Kim YS
    Am J Clin Pathol; 1998 Mar; 109(3):302-8. PubMed ID: 9495202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
    Trauner M; Fickert P; Halilbasic E; Moustafa T
    Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis.
    Caraceni P; Viola A; Piscitelli F; Giannone F; Berzigotti A; Cescon M; Domenicali M; Petrosino S; Giampalma E; Riili A; Grazi G; Golfieri R; Zoli M; Bernardi M; Di Marzo V
    Liver Int; 2010 Jul; 30(6):816-25. PubMed ID: 19840245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoid drugs and enhancement of endocannabinoid responses: strategies for a wide array of disease states.
    Karanian DA; Bahr BA
    Curr Mol Med; 2006 Sep; 6(6):677-84. PubMed ID: 17022737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocannabinoids, cannabinoid receptors and inflammatory stress: an interview with Dr. Pál [corrected] Pacher. Interviewed by Helene F. Rosenberg.
    Pacher PA
    J Leukoc Biol; 2007 Dec; 82(6):1390-2. PubMed ID: 18040082
    [No Abstract]   [Full Text] [Related]  

  • 16. Mixed hepatocellular-cholangiocarcinoma may derive from "hepatogones".
    Hunt JP; Varnholt H
    Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):105; author reply 105-6. PubMed ID: 18234649
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of cannabinoids in chronic liver diseases.
    Parfieniuk A; Flisiak R
    World J Gastroenterol; 2008 Oct; 14(40):6109-14. PubMed ID: 18985799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
    Abe N; Watanabe T; Izumisato Y; Suzuki Y; Masaki T; Mori T; Sugiyama M; Fusco A; Atomi Y
    J Gastroenterol; 2003; 38(12):1144-9. PubMed ID: 14714251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the endocannabinoid system in liver diseases.
    Caraceni P; Domenicali M; Giannone F; Bernardi M
    Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):65-77. PubMed ID: 19285261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocannabinoid overactivity and intestinal inflammation.
    Di Marzo V; Izzo AA
    Gut; 2006 Oct; 55(10):1373-6. PubMed ID: 16966693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.